The genomic landscape of response to EGFR blockade in colorectal cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are the monoclonal antibodies cetuximab and panitumumab, which prevent epidermal growth factor receptor (EGFR) activation. Recent studies have identified alterations in KRAS and other genes as likely mechanisms of primary and secondary resistance to anti-EGFR antibody therapy. Despite these efforts, additional mechanisms of resistance to EGFR blockade are thought to be present in colorectal cancer and little is known about determinants of sensitivity to this therapy. To examine the effect of somatic genetic changes in colorectal cancer on response to anti-EGFR antibody therapy, here we perform complete exome sequence and copy number analyses of 129 patient-derived tumour grafts and targeted genomic analyses of 55 patient tumours, all of which were KRAS wild-type. We analysed the response of tumours to anti-EGFR antibody blockade in tumour graft models and in clinical settings and functionally linked therapeutic responses to mutational data. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Novel alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade. Amplifications and sequence changes in the tyrosine kinase receptor adaptor gene IRS2 were identified in tumours with increased sensitivity to anti-EGFR therapy. Therapeutic resistance to EGFR blockade could be overcome in tumour graft models through combinatorial therapies targeting actionable genes. These analyses provide a systematic approach to evaluating response to targeted therapies in human cancer, highlight new mechanisms of responsiveness to anti-EGFR therapies, and delineate new avenues for intervention in managing colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in late-line therapy, only 12–17% of patients have durable responses to anti-EGFR monotherapy [4]”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Gene mutations downstream of the EGFR signalling pathway, including RAS/RAF/MEK and PI3K/AKT/mTOR, significantly contribute to drug resistance [9–11].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [10]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is supported by our observation, consolidated after monitoring hundreds of mCRC PDXs exposed to cetuximab (10, 25, 27, 29, 30), that complete responses are exceptional events.”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“A growing number of studies suggest that mutations in the extracellular domain (ECD) of the EGFR, such as S492R, G465E, R451C and K467T, prevent binding cetuximab and make CRC resistant to anti-EGFR mAbs [141,142,143,144].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288 · cited 1×
“Sequence reads were aligned against the human reference genome (version hg18) using ELAND with additional realignment of select regions using the Needleman-Wunsch method 35 .”
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“A mutation in the tumour was identified as a candidate somatic mutation only when (1) distinct paired reads contained the mutation in the tumour, (2) the number of distinct paired reads containing a particular mutation in the tumour was at least 2% of the total distinct read pairs for targeted analyses and 10% of read…”
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Self-citationPDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 6×
“Common CRC driver genes were identified at expected frequencies in the tumours analysed (Supplementary Tables 3–5).”
InfluentialSelf-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Coiffier, B., Osmanov, E. A., Hong, X., Scheliga, A. A. D. S., Mayer, J., Offner, F., Rule, S. A., Teixeira, A., Walewski, J. A., Vos, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045 · Cited by 1,631
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Cited by
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
“The response to current anti-EGFR therapy can be modified by factors such as: the type of somatic EGFR mutations, EGFR gene amplification, increased autocrine EGFR ligands, and mutations in EGFR signaling pathway proteins ERBB2, K-RAS, B-RAF, PI3KCA, PTEN, and BIM (reviewed in [375,379]).”
BackgroundConsensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
“(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (http://creativecommons.”
BackgroundSelf-citationEvolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 896
“Acquisition of somatic resistance mutations is a common mechanism of therapeutic resistance to targeted therapies (23).”
BackgroundMethodSelf-citationHigh grade serous ovarian carcinomas originate in the fallopian tube
Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 759
Self-citationInterrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., et al. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.140 · Cited by 657
Self-citationFrom tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Self-citationParikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0561-9 · Cited by 518
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
“Taking advantage of our molecularly and therapeutically annotated CRC patient-derived bio-bank (25-27), in a cohort of more than one hundred patient-derived organoids (PDO), we selected three different KRAS G12C mutant PDOs and one KRAS G12D mutant PDO (as negative control) and tested the effects of single agents AMG5…”
MethodSelf-citationRational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Genetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
“…2011), breast cancer (Marangoni et al , 2007), melanoma (Kemper et al , 2015; Girotti et al , 2016), prostate cancer (Yoshida et al , 2005; Qu et al , 2014), and colorectal cancer (Bertotti et al , 2011, 2015; Bardelli et al , 2013; Kavuri et al , 2015; Misale et al , 2015; Zanella et al , 2015).”
Adaptive mutability of colorectal cancers in response to targeted therapies
Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., et al. (2019) · Science · doi:10.1126/science.aav4474 · Cited by 433
Self-citationLu, Y., Zhao, X., Liu, Q., Li, C., Graves-Deal, R., Cao, Z., Singh, B., Franklin, J. L., Wang, J., Hu, H., et al. (2017) · Nature Medicine · doi:10.1038/nm.4424 · Cited by 425
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
KATOH, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2620 · Cited by 405
“Resistance to EGFR-targeted therapy occurs based on paracrine FGF signaling from tumor-stromal cells (82) or activating FGFR alterations, such as FGFR1 amplification and FGFR3 mutation, in cancer cells (129,130).”
BackgroundTumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Russo, M., Siravegna, G., Blaszkowsky, L. S., Corti, G., Crisafulli, G., Ahronian, L. G., Mussolin, B., Kwak, E. L., Buscarino, M., Lazzari, L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1283 · Cited by 405
“K57 in MEK1 were recently implicated in de novo resistance to antiEGFR antibodies in CRC(14, 15), they have not previously been observed in the setting of acquired resistance.”
BackgroundSelf-citationTesta, U., Pelosi, E., & Castelli, G. (2018) · Medical Sciences · doi:10.3390/medsci6020031 · Cited by 374
“The exome analysis of a wide group of CRC patients undergoing EGFR blockade showed additional mechanisms of resistance in addition to those commonly reported, including mutations other than those commonly reported, such as mutations of ERBB2, EGFR, FGFR1, PDGFRA and MAP2K1; furthermore, amplifications and mutations in…”
ResultKnown and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
Comoglio, P. M., Trusolino, L., & Boccaccio, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0002-y · Cited by 381
Self-citationSchütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339
Treatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Sartore-Bianchi, A. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 329
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Isella, C., Brundu, F., Bellomo, S. E., Galimi, F., Zanella, E., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 302
“We and others have identified a number of genetic alterations that associate with resistance to cetuximab 12,36–39 .”
InfluentialSelf-citationNguyen, H. M., Vessella, R. L., Morrissey, C., Brown, L. G., Coleman, I. M., Higano, C. S., Mostaghel, E. A., Zhang, X., True, L. D., Lam, H.-M., et al. (2017) · The Prostate · doi:10.1002/pros.23313 · Cited by 300
“The ability to comprehensively interrogate genomes and gene expression has enabled the underlying genetic drivers of tumor behavior to be integrated with assessments of response and resistance to drugs and to develop biomarkers predictive of treatment outcome [15].”
BackgroundGenomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L., McKinney, M., Korn, W. M., Atreya, C. E., Banks, K. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1009 · Cited by 295
“AMP G12A G12C G13D Q61H Q61H Q61K V600E V600E Q61H Q61H Q61K BRAF K57T K57TMEK1 ERK NRASKRAS BRAF MEK1 ERK NRASKRAS BRAF MEK1 ERK NRASKRAS EGFR EGFRMET AMPERBB2 AMP ERBB2 AMP KIT AMP MET AMP 20 40 60 1 1 5 2 2 1 1 8 11 1 1 4 2 1 12 1 11 13 1 2 1 1 1 2 2 1 1 10 16 5 2 4 5 4 4 1 1 3 22 3 1 1 1 3 1 1 5 3 3 314211 41 40 3…”
BackgroundInfluentialSartore-Bianchi, A., Pietrantonio, F., Lonardi, S., Mussolin, B., Rua, F., Crisafulli, G., Bartolini, A., Fenocchio, E., Amatu, A., Manca, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01886-0 · Cited by 268
Self-citationA Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
“For allosteric (type IIB), non-ATP-competitive kinase inhibitors, resistance mutations outside of the gatekeeper residue can alter the intrinsic activity of the target kinase, as seen in resistance toMEK inhibitors (Emery et al., 2009), or interfere with drug binding, as observed with resistance to the BTK inhibitor i…”
InfluentialDeterminants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 258
Parseghian, C. M., Loree, J. M., Morris, V. K., Liu, X., Clifton, K. K., Napolitano, S., Henry, J. T., Pereira, A. A., Vilar, E., Johnson, B., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy509 · Cited by 253
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
“One case acquired an FGFR1 amplification and one an FGFR3 mutation with unclear relevance for resistance.”
BackgroundResultInfluentialTargeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Sartore-Bianchi, A., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 244
“These genetic alterations confer resistance to EGFR-targeted therapies in patients with CRC [1, 53, 54], although currently only selection based on RAS status is recommended for excluding patients from anti-EGFR treatment [55–57].”
BackgroundMethodInfluentialSelf-citationLenz, H.-J., Ou, F.-S., Venook, A. P., Hochster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Bertagnolli, M. M., Blanke, C. D., Zemla, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02258 · Cited by 246
“These tumors are characterized by activated EGFR pathways that render them sensitive to cetuximab.(27,28) Even in KRASwild-type tumor, not all patient respond to cetuximab.”
BackgroundZhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Self-citationS3-Leitlinie – Kolorektales Karzinom: Langversion 2.0 – November 2017–AWMF-Registernummer: 021/007OL
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T., Nothacker, M., Porschen, R., Rödel, C., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 241
Richman, S. D., Southward, K., Chambers, P., Cross, D., Barrett, J., Hemmings, G., Taylor, M., Wood, H., Hutchins, G., Foster, J. M., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4679 · Cited by 241
“Bertotti et al [25] provided early evidence using HER2-amplified tumour xenografts, which demonstrated resistance to cetuximab.”
BackgroundBarault, L., Amatu, A., Siravegna, G., Ponzetti, A., Moran, S., Cassingena, A., Mussolin, B., Falcomatà, C., Binder, A. M., Cristiano, C., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313372 · Cited by 234
Self-citationKhan, K. H., Cunningham, D., Werner, B., Vlachogiannis, G., Spiteri, I., Heide, T., Mateos, J. F., Vatsiou, A., Lampis, A., Damavandi, M. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0891 · Cited by 225
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Cai, W.-Q., Zeng, L.-S., Wang, L.-F., Wang, Y.-Y., Cheng, J.-T., Zhang, Y., Han, Z.-W., Zhou, Y., Huang, S.-L., Wang, X.-W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01249 · Cited by 196
“Studies have shown that in KRAS wild-type CRC patients, the final response to EGFR monoclonal antibody treatment is only about 15% (96, 101).”
BackgroundResultInfluentialA Nanobody‐Conjugated DNA Nanoplatform for Targeted Platinum‐Drug Delivery
Wu, T., Liu, J., Liu, M., Liu, S., Zhao, S., Tian, R., Wei, D., Liu, Y., Zhao, Y., Xiao, H., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909345 · Cited by 185
Vaz, M., Hwang, S. Y., Kagiampakis, I., Phallen, J., Patil, A., O'Hagan, H. M., Murphy, L., Zahnow, C. A., Gabrielson, E., Velculescu, V. E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.006 · Cited by 191
Self-citationYoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178
Self-citationNext generation sequencing‐based gene panel tests for the management of solid tumors
Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2019) · Cancer Science · doi:10.1111/cas.13837 · Cited by 177
Danilova, L., Anagnostou, V., Caushi, J. X., Sidhom, J.-W., Guo, H., Chan, H. Y., Suri, P., Tam, A., Zhang, J., Asmar, M. E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0129 · Cited by 168
“4 kit (Agilent, Santa Clara, CA) according to the manufacturers’ instructions as previously described (17-20).”
MethodSelf-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data
Kluin, R. J. C., Kemper, K., Kuilman, T., de Ruiter, J. R., Iyer, V., Forment, J. V., Cornelissen-Steijger, P., de Rink, I., ter Brugge, P., Song, J.-Y., et al. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2353-5 · Cited by 162
“Despite its limitations [8, 10], the wide applicability of PDX, and more generally of tumor xenografts, is reflected by tens of thousands publications describing numerous biological, mechanistic and preclinical applications [11 – 16].”
BackgroundRadiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Siravegna, G., Lazzari, L., Crisafulli, G., Sartore-Bianchi, A., Mussolin, B., Cassingena, A., Martino, C., Lanman, R. B., Nagy, R. J., Fairclough, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.004 · Cited by 159
Self-citationMolecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 152
“In patients with CRC, EGFR mutations (S492R [154], G465R, and G465E [148]) in exon 12, which encodes the extracellular domain of EGFR, are associated with resistance.”
BackgroundMethodInfluentialp53 and metabolism: from mechanism to therapeutics
Simabuco, F. M., Morale, M. G., Pavan, I. C. B., Morelli, A. P., Silva, F. R., & Tamura, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.25267 · Cited by 176
“Evidences suggest that these agents may be useful for clinical purposes, although studies suggest that they may increase resistance to other chemotherapeutics [350].”
Towards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 165
“This strategy has led to reconsidering the biological underpinnings of a poor-prognosis CRC transcriptional subtype (CMS4) that was initially assumed to include stem-like tumours featuring traits of cancer cell epithelial-mesenchymal transition 47,48,49 .”
Self-citationLiao, M., Qin, R., Huang, W., Zhu, H.-P., Peng, F., Han, B., & Liu, B. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01260-0 · Cited by 141
DNA in serum extracellular vesicles is stable under different storage conditions
Jin, Y., Chen, K., Wang, Z., Wang, Y., Liu, J., Lin, L., Shao, Y., Gao, L., Yin, H., Cui, C., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2783-2 · Cited by 136
“Therefore, clinicians might use them to guide individual treatments [51].”
Siravegna, G., Sartore-Bianchi, A., Nagy, R. J., Raghav, K., Odegaard, J. I., Lanman, R. B., Trusolino, L., Marsoni, S., Siena, S., & Bardelli, A. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3389 · Cited by 135
“Use of the anti-EGFR mAbs cetuximab and panitumumab has improved progression-free survival (PFS) and OS in patients who are negative for KRAS, NRAS, and BRAFmutations; however, these therapies are inevitably followed by disease progression (2).”
BackgroundSelf-citationKaufman, N. E. M., Dhingra, S., Jois, S. D. S., & Vicente, M. G. H. (2021) · Molecules · doi:10.3390/molecules26041076 · Cited by 143
Current Targeted Therapy for Metastatic Colorectal Cancer
Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 149
CD44v6 engages in colorectal cancer progression
Ma, L., Dong, L., & Chang, P. (2019) · Cell Death & Disease · doi:10.1038/s41419-018-1265-7 · Cited by 128
Liu, J. F., Palakurthi, S., Zeng, Q., Zhou, S., Ivanova, E., Huang, W., Zervantonakis, I. K., Selfors, L. M., Shen, Y., Pritchard, C. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1237 · Cited by 127
“Potential somatic mutations and copy number alterations excluding mouse-specific variants were identified usingVariantDx customsoftware as describedpreviously (14, 15).”
BackgroundMethodSelf-citationResponse to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
Yaeger, R., Kotani, D., Mondaca, S., Parikh, A. R., Bando, H., Van Seventer, E. E., Taniguchi, H., Zhao, H., Thant, C. N., de Stanchina, E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2004 · Cited by 125
“In addition to RAS mutations, activation of other RTKs leads to resistance to anti-EGFR therapy (35, 36).”
BackgroundParseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121
“continues to be an active area of investigation in rechallenge studies.(46,47,55,66-69) In contrast to RAS mutations, ectodomain (ECD) mutations are almost never seen in untreated tumors.”
BackgroundLi, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
“Some changes that have been rarely reported include NTRK gene fusion, IRS2 amplification or mutations, FGFR1 and MAP2K1 mutations, and the low expression of the Bcl-2interacting mediator of cell death (Bim) [28, 150, 151]; the occurrence of unknown mutations mostly relates to dMMR.”
BackgroundSelf-citationIntegrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 113
Proteomic profiling of human plasma for cancer biomarker discovery
Huang, Z., Ma, L., Huang, C., Li, Q., & Nice, E. C. (2016) · PROTEOMICS · doi:10.1002/pmic.201600240 · Cited by 124
Self-citationDNA copy number changes define spatial patterns of heterogeneity in colorectal cancer
Mamlouk, S., Childs, L. H., Aust, D., Heim, D., Melching, F., Oliveira, C., Wolf, T., Durek, P., Schumacher, D., Bläker, H., et al. (2017) · Nature Communications · doi:10.1038/ncomms14093 · Cited by 110
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 115
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S., & Bekaii-Saab, T. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8196 · Cited by 100
Self-citationTargeting the Microenvironment in Advanced Colorectal Cancer
Tauriello, D. V. F., & Batlle, E. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.001 · Cited by 116
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
Beekhof, R., van Alphen, C., Henneman, A. A., Knol, J. C., Pham, T. V., Rolfs, F., Labots, M., Henneberry, E., Le Large, T. Y., de Haas, R. R., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188250 · Cited by 97
“The patient-derived xenograft tumor tissue used in this study was derived from xenograft models that have been described before (Bertotti et al , 2015).”
MethodSelf-citationThierry, A. R., Pastor, B., Jiang, Z.-Q., Katsiampoura, A. D., Parseghian, C., Loree, J. M., Overman, M. J., Sanchez, C., Messaoudi, S. E., Ychou, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0232 · Cited by 97
“Bertotti et al (40) characterized secondary resistance to EGFR blockade in mCRC and observed that alterations in KRAS, NRAS, and BRAF were important mechanisms of resistance.”
Pellino, G., Gallo, G., Pallante, P., Capasso, R., Stefano, A. D., Maretto, I., Malapelle, U., Qiu, S., Nikolaou, S., Barina, A., et al. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/2397863 · Cited by 105
“[218] performed a whole-exome analysis of 129 tumors in patient-derived xenografts detecting mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 that could be potential mechanisms of primary resistance to anti-EGFR antibody therapy in CRC.”
MethodArena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5640 · Cited by 93
Self-citationExploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges
Buikhuisen, J. Y., Torang, A., & Medema, J. P. (2020) · Oncogenesis · doi:10.1038/s41389-020-00250-6 · Cited by 107
Collazo-Lorduy, A., Castillo-Martín, M., Wang, L., Patel, V. G., Iyer, G., Jordan, E., Al‐Ahmadie, H. A., Leonard, I., Oh, W. K., Zhu, J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.04.037 · Cited by 92
“Predictors of sensitivity have proven even more elusive; analyses using model systems and human specimens have identified putative treatment response biomarkers such as EGFR amplification, alterations in the tyrosine kinase adaptor gene IRS2, and increased EGFR ligand expression [7–9].”
PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
Xu, Y., Gao, Z., Hu, R., Wang, Y., Wang, Y., Su, Z., Zhang, X., Yang, J., Mei, M., Ren, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002699 · Cited by 102
Wang, J., Yang, S., Cai, X., Dong, J., Chen, Z., Wang, R., Zhang, S., Cao, H., Lu, D., Jin, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12589 · Cited by 91
“It was reported recently that amplification of MET, FGFR1 and ERBB2 was involved in EGFR therapeutic resistance in colorectal cancer [23].”
BackgroundMauri, G., Pizzutilo, E. G., Amatu, A., Bencardino, K., Palmeri, L., Bonazzina, E. F., Tosi, F., Carlo Stella, G., Burrafato, G., Scaglione, F., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.006 · Cited by 90
Self-citationPrognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Sawada, K., Nakamura, Y., Yamanaka, T., Kuboki, Y., Yamaguchi, D., Yuki, S., Yoshino, T., Komatsu, Y., Sakamoto, N., Okamoto, W., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.006 · Cited by 85
A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers
Cheng, R., Li, F., Zhang, M., Xia, X., Wu, J., Gao, X., Zhou, H., Zhang, Z., Huang, N., Yang, X., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00726-7 · Cited by 92
“Alternative therapies against the upstream growth factor receptors such as EGFR have been applied in NSCLC and colon cancer, but those patients with RAS mutations were excluded.(7) Moreover, secondary resistance to EGFR inhibitors in patients with wild-type RAS is often driven by acquired RAS mutations.”
Zhu, J., Ji, L., Chen, Y., Li, H., Huang, M., Dai, Z., Wang, J., Xiang, D., Fu, G., Lei, Z., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01354-9 · Cited by 93
“Some KRAS and BRAF wild-type CRC patients also could not benefit from anti-EGFR agents because of the effect from other relevant pathways and potential pathway crosstalk [82].”
BackgroundGlobal Inequities in Precision Medicine and Molecular Cancer Research
Drake, T. M., Knight, S. R., Harrison, E. M., & Søreide, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00346 · Cited by 90
“In the case of colorectal cancer, both type and location of KRAS mutations are known to predict response to EGFR inhibition in colorectal cancer (72).”
BackgroundLupo, B., Sassi, F., Pinnelli, M., Galimi, F., Zanella, E. R., Vurchio, V., Migliardi, G., Gagliardi, P. A., Puliafito, A., Manganaro, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8313 · Cited by 83
“Residual colorectal tumors after EGFR blockade are made of slowly cycling cells that resemble EGFR-inhibited normal intestinal cells For population-level assessment of residual disease after cetuximab therapy we deployed a series of 279 mCRC PDXs, derived from as many patients, part of which had been used in previous…”
BackgroundMethodInfluentialSelf-citationRAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 78
“Interestingly, alterations in the tyrosine kinase receptor adaptor gene ISR2 may be associated with increased sensitivity to anti-EGFR agents (92).”
BackgroundBray, S. M., Lee, J., Kim, S. T., Hur, J. Y., Ebert, P. J., Calley, J. N., Wulur, I. H., Gopalappa, T., Wong, S. S., Qian, H.-R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51981-5 · Cited by 82
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3440 · Cited by 74
“In colorectal cancer, seminal studies have already set the stage for pharmacogenomic analyses and association of PDX genotype with targeted therapy response (14, 18).”
InfluentialSelf-citationColorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation
Fessler, E., & Medema, J. P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.008 · Cited by 92
Nagahashi, M., Wakai, T., Shimada, Y., Ichikawa, H., Kameyama, H., Kobayashi, T., Sakata, J., Yagi, R., Sato, N., Kitagawa, Y., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0387-8 · Cited by 81
“For instance, the importance of genomic evaluation of RAS and RAF for advanced CRC patients has been widely accepted, since it has been revealed that tumors with RAS or RAF mutations show resistance to anti-EGFR therapies [10].”
BackgroundInfluentialXu, W., Song, C., Wang, X., Li, Y., Bai, X., Liang, X., Wu, J., & Liu, J. (2021) · Aging · doi:10.18632/aging.103669 · Cited by 77
“com 229 AGING of EGFR and suppresses the activation of a series of downstream signaling pathways [7].”
Backgroundc-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors
Strippoli, A., Cocomazzi, A., Basso, M., Cenci, T., Ricci, R., Pierconti, F., Cassano, A., Fiorentino, V., Barone, C. A., Bria, E., et al. (2020) · Cancers · doi:10.3390/cancers12030638 · Cited by 77
Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons
Tan, C. R. C., Zhou, L., & El‐Deiry, W. S. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0320-y · Cited by 83
Helden, E. J. V., Angus, L., van Oordt, C. W. M. D. H., Heideman, D. A. M., Boon, E., van Es, S. C., Radema, S. A., van Herpen, C. M. L., de Groot, D. J. A., de Vries, E. G. E., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12550 · Cited by 83
“All of these EGFR mutations are located in domain III of the receptor and alter the epitope to which cetuximab binds, thereby inhibiting binding of cetuximab to EGFR (Arena et al., 2015, 2016; Bertotti et al., 2015; Esposito et al., 2013; Sickmier et al., 2016; Voigt et al., 2012).”
BackgroundGupta, R., Othman, T., Chen, C., Sandhu, J., Ouyang, C., & Fakih, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0441 · Cited by 70
Gupta, R., Meric‐Bernstam, F., Rothe, M., Garrett-Mayer, E. S., Mangat, P. K., D’Andre, S. D., Ahn, E. R., O'Lone, R., Halabi, S., Grantham, G. N., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00306 · Cited by 90
Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A. H., Frank, S., Holz, B., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5110 · Cited by 69
“The impact of copy number alterations on therapy resistance has already been proven in different cancer types and it is known that patients with gene amplifications can become resistant to drug therapies, resulting in a poor prognosis [38].”
BackgroundThe design, analysis and application of mouse clinical trials in oncology drug development
Guo, S., Jiang, X., Mao, B., & Li, Q.-X. (2019) · BMC Cancer · doi:10.1186/s12885-019-5907-7 · Cited by 68
Self-citationEnhancing the landscape of colorectal cancer using targeted deep sequencing
Lee, C. S., Song, I. H., Lee, A., Kang, J., Lee, Y. S., Lee, I. K., Song, Y. S., & Lee, S. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-87486-3 · Cited by 64
Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells
Zhang, S., Zhang, Y., Qu, J., Che, X., Fan, Y., Hou, K., Guo, T., Deng, G., Song, N., Li, C., et al. (2018) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20176472 · Cited by 63
Li, H., Wang, J., Yi, Z., Li, C., Wang, H., Zhang, J., Wang, T., Nan, P., Lin, F., Xu, D., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.045 · Cited by 65
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
Tapia-Galisteo, A., Sánchez-Rodríguez, I., Aguilar-Sopeña, Ó., Harwood, S. L., Narbona, J., Ferreras-Gutiérrez, M., Navarro, R., Martín-García, L., Corbacho, C., Compte, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2034355 · Cited by 74
“Emergence of mutations in the EGFR ectodomain, located in the region of interaction with cetuximab, may disturb this interface and confer resistance to the treatment.(35,36) Interestingly, a subset of EGFR mutations preventing binding to cetuximab are still permissive for interaction with panitumumab, the second anti-…”
BackgroundClinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
Bagchi, A., Haidar, J. N., Eastman, S. W., Vieth, M., Topper, M., Iacolina, M. D., Walker, J. M., Forest, A., Shen, Y., Novosiadly, R. D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0575 · Cited by 60
“Additional somatic mutations that map to the cetuximab epitope on EGFR have been seen in cetuximab-resistant colorectal tumors: G441/465R, G441/465E, K443/467T (14, 16), or identified in colorectal cancer cell lines: S440/464L and I467/491M (14).”
BackgroundDurinikova, E., Buzo, K., & Arena, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01981-z · Cited by 67
Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer
Shan, J., Xuan, Y., Zhang, Q., Zhu, C., Liu, Z., & Zhang, S. (2016) · Protein & Cell · doi:10.1007/s13238-016-0295-0 · Cited by 63
“Despite its favorable clinical efficacy, dose-limiting side effect (such as neuropathy) of oxaliplatinbased chemotherapy prevents administration of the full efficacious dosage and frequently leads to treatment withdrawal (Avan et al., 2015; Martinez-Balibrea et al., 2015).”
Metadata
- Authors
- Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., Niknafs, N., Nesselbush, M., Lytle, K., Sassi, F., Cottino, F., Migliardi, G., Zanella, E. R., Ribero, D., Russolillo, N., Mellano, A., Muratore, A., Paraluppi, G., Salizzoni, M., Marsoni, S., Kragh, M., Lantto, J., Cassingena, A., Li, Q. K., Karchin, R., Scharpf, R., Sartore-Bianchi, A., Siena, S., Diaz, L. A., Trusolino, L., & Velculescu, V. E.
- Affiliations
- Istituto Nazionale Biostrutture e Biosistemi (IT)
- Johns Hopkins University (US)
- Candiolo Cancer Institute (IT)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Symphogen (Denmark) (DK)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- University of Milan (IT)
- Corresponding author
- Bertotti, Andrea
- Trusolino, Livio
- Velculescu, Victor E.
- ORCID
- Bertotti, Andrea
- Papp, Eniko
- Jones, Siân
- Adleff, Vilmos
- Anagnostou, Valsamo
- Lupo, Barbara
- Sausen, Mark
- Phallen, Jillian
- Hruban, Carolyn A.
- Tokheim, Collin
- Niknafs, Noushin
- Nesselbush, Monica
- Sassi, Francesco
- Cottino, Francesca
- Migliardi, Giorgia
- Zanella, Eugenia R.
- Ribero, Dario
- Russolillo, Nadia
- Mellano, Alfredo
- Muratore, Andrea
- Salizzoni, Mauro
- Marsoni, Silvia
- Kragh, Michael
- Lantto, Johan
- Cassingena, Andrea
- Li, Qing Kay
- Karchin, Rachel
- Scharpf, Robert
- Siena, Salvatore
- Diaz, Luis A.
- Trusolino, Livio
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2015-09-30
- Volume
- 526
- Issue
- 7572
- Pages
- 263-267
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4878148
- OpenAlex
- W2102354469
- Cited by
- 479
- References
- 41
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 35 · 2022: 47 · 2021: 50 · 2020: 47 · 2019: 59 · 2018: 56 · 2017: 57 · 2016: 43 · 2015: 3
- FWCI
- 23.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-02-16)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ca121113-15)
- National Cancer Institute (R01-CA121113, CA-121113, P30CA006973)
- National Institute of General Medical Sciences (T32GM007057)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibition, anti-EGFR antibody therapy, cetuximab, panitumumab, treatment resistance, primary resistance, somatic mutations, ERBB2, FGFR1, PDGFRA, MEK1, KRAS wild-type
- MeSH terms
- Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Mutation, Colorectal Neoplasms, Genome, Human, Proto-Oncogene Proteins p21(ras), Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Receptor, Platelet-Derived Growth Factor alpha, Xenograft Model Antitumor Assays, Genomics, MAP Kinase Kinase 1, Mice, Receptor, Fibroblast Growth Factor, Type 1, Insulin Receptor Substrate Proteins, DNA Copy Number Variations, Molecular Targeted Therapy, Exome, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.